Omomyc is a modified miniprotein that inhibits the activity of MYC, developed as an experimental anti-cancer approach. The clinical product OMO-103 contains a miniprotein composed of 91 amino acids and was studied in an early human study. The current results confirm the biological activity and justify further clinical studies, but do not prove that Omomyc is a broadly effective method of treating cancer. [1] [2]
The most important thing is to distinguish between the inhibition of a molecular program associated with cancer and the improvement of patient treatment outcomes. Confirmation of the effect with a molecular target is valuable, but survival, symptoms, sustained disease control, and safety require separate clinical evaluation.
At the beginning, it is necessary to distinguish between the molecular target, the modified inhibitor, and the product clinically studied. MYC is a cellular transcription factor. Omomyc is a modified protein designed to disrupt the molecular interactions of this factor. OMO-103 is the name of a specific product being clinically developed. These categories are related but not synonymous. The search result for MYC does not necessarily refer to Omomyc, and the study of the Omomyc expression construct does not necessarily characterize OMO-103.
This distinction affects literature searches. Research databases can index the same research program under the terms Omomyc, OMO-103, inhibition of MYC, inhibition of transcription factors, or the names of individual tumors. A repetitive review should document the search terms, dates, and inclusion criteria. Then, each publication should be classified according to whether it assesses purified protein, intracellular expression system, compound combination, biomarker, or actual clinical product. This avoids confusion between the large number of studies on MYC and the number of direct clinical evidence regarding Omomyc.
The term „experimental anti-cancer approach” also requires precision. It describes the goal of the research program, not the established therapeutic outcome. The molecular identity can be well documented, even if clinical efficacy remains uncertain. Separating these statements increases the value of both the scientific description and the review of the evidence.
What is Omomyc? Names, synonyms and identity
Omomyc was designed based on the functional region MYC, a transcription factor involved in regulating gene expression programs. It acts as an inhibitor of the MYC function, rather than as a supplement providing proper activity of MYC. The name refers to the modified research molecule, not the naturally occurring peptide isolated from the tissue. [1]
OMO-103 is a developmental name associated with the recombinant omomyc miniprotein used in human studies. Previous work involved genetically modified expression in experimental systems, whereas later studies analyzed the delivery of purified protein. These approaches are based on a common biological concept, but differ in the way the inhibitor reaches the cells. The transgenic experiment is not automatically a study of pharmacological exposure.
The terms „MYC inhibitor” and „Omomyc” should also not be treated as synonyms. Inhibition of MYC is a broad research goal, and other experimental strategies may utilize different molecules, targets, or intermediate mechanisms. Evidence derived from such studies cannot simply be added to Omomyc’s clinical documentation.
Similarly, an internet product labeled as „Omomyc peptide” is not considered equivalent to OMO-103 solely on the basis of the name. Confirmation of equivalence would require a much more comprehensive comparison of identity, manufacturing process, formulation, biological activity, and specifications regarding clinical use.
Proteins and peptides are not separated by a commonly accepted numerical boundary. Both groups consist of amino acids linked by peptide bonds. In this case, the length of 91 residues, the modified protein domain, and the function-dependent interactions between molecules make the term „miniprotein” more informative. It conveys more than the general term „peptide,” which can also describe much shorter synthetic chains with unrelated functions.
The finished experimental product is also not equivalent to an isolated molecular unit. Buffers, concentration, container, stability, and production controls can affect the properties of the material being studied. The description of the molecule’s composition does not confirm the identity of the unbound sample. Moreover, documenting the purity of the product does not prove that it reaches the intracellular target or improves clinical outcomes.
Omomyc belongs to experimental strategies aimed at intracellular protein networks. Conceptually, it differs from a receptor agonist, an antibody binding an antigen on the cell surface, or a conventional cytotoxic molecule. This is a functional distinction, not a claim of greater selectivity or safety. Any comparative advantage would require direct evidence.
How is Omomyc classified? Peptide, protein, mixture, or other substance?
The most precise classification is „modified miniprotein.” The clinical publication describes OMO-103 as a miniprotein composed of 91 amino acids. Although proteins are composed of amino acids linked by peptide bonds, and the broad terminology sometimes refers to such molecules as peptides, presenting Omomyc as an undefined short peptide omits important structural and functional information. [2]
It is not a steroid, a small molecule drug, a cosmetic peptide mixture, or an antibody. The administration of purified protein is also not equivalent to gene editing. The strategy aims to change the activity of the transcriptional network, and not to permanently rewrite the patient's DNA sequence.
The distinction between the molecule and the product remains important. Omomyc represents a modified molecular concept, whereas OMO-103 used in the clinical study is an experimental product with a specific production and formulation context. The molecular classification does not confirm regulatory approval, qualification for treatment, or suitability for use without supervision.
An experimental protein can be well characterized chemically, yet exhibit an uncertain clinical balance of benefits and risks. Identity and efficacy are separate questions. Accurate knowledge of what is being administered enables interpretation of the experiment, but does not dictate its outcome.
Why does the domain associated with MYC matter?
MYC participates in gene regulation through interactions with other proteins and regulatory regions associated with DNA. The basic helix–loop–helix leucine zipper (bHLH-LZ) region is important because it is involved in the interactions necessary for this activity. The introduction of mutations in such a region can alter the binding of molecular partners and subsequent transcriptional activity. However, the presence of a recognizable domain does not guarantee intended activity in every experimental preparation.
The physical state of a protein is important alongside its amino acid sequence. Folding, aggregation, degradation, and interactions with formulation components can influence the amount of material that retains biological activity. Therefore, analytical confirmation of the sequence is not the same as functional confirmation. A reliable characterization program should distinguish molecular identity, structural integrity, purity, content, and appropriate biological activity assay using methods appropriate for each purpose.
Intracellular delivery and exposure
The target point of action is located inside the cell, which creates a delivery problem that affinity alone cannot solve. The protein must maintain sufficient integrity, penetrate the appropriate cells, and reach the region where molecular interaction occurs. Experiments involving uptake by cultured cells provide information, but do not measure distribution in the heterogeneous structure of a human tumor. Tissue perfusion, extracellular barriers, cellular uptake, and elimination can all influence exposure.
The study may confirm cell entry in one model, but does not prove identical entry into every subtype of the tumor. Similarly, observing changes in the expression of genes associated with MYC can support the hypothesis of a biological effect, without revealing how much intact protein has reached each cell. Distinguishing these measurements prevents over-extending conclusions based on an attractive mechanism.
The structure and composition of Omomyc – what has been established?
Published studies describe Omomyc as a molecule derived from the bHLH-LZ region of the MYC protein, containing four mutations in the leucine-rich site. This region is involved in interactions related to the transcriptional activity of MYC. The modifications alter the domain's behavior in a way that enables disruption of the MYC network. [1]
Full research identity encompasses more than the length of the chain. Significance is given to sequence, folding, binding of molecular partners, purity, and retained activity. Two proteins with identical number of residues can have completely different functions, and the label alone does not confirm the correct characteristics of the produced sample.
This article does not present a sequence ready for synthesis or derive the chemistry of the end groups from commercial offers. A clinically relevant point of reference is the material described in the development literature and study documentation. Experimental versions containing labels, labels, or delivery modifications should be clearly identified, rather than being combined with the clinical product without distinction.
Cell penetration is a particularly important part of structural characterization. The transcriptional factor inhibitor must reach the appropriate intracellular compartment. Purified Omomyc demonstrated cell penetration in experimental models, creating a bridge between genetic studies confirming the concept and the experimental protein that could be delivered. This observation does not mean that every formulation or route of administration will provide identical exposure. [1]
Evidence is best organized according to the questions that individual experiments can answer. Molecular and cellular studies analyze interactions with the target and subsequent biological changes. Animal models can combine exposure with tumor behavior in a living experimental organism. Phase I human studies primarily serve to early characterize safety, pharmacology, and signals justifying further studies. These categories complement each other, but are not equivalent levels of evidence.
It is also important to separate the declared objective of the study from its results. A registered study may involve the analysis of a tumor biopsy or the assessment of the response, but such an objective is not a reported result. Similarly, a published article may contain many endpoints, but the previously defined primary objectives should be given special importance. Each percentage or number of responses should be accompanied by an appropriate denominator and a period of observation.
Research on Omomyc – evidence in humans, animals and in the laboratory
Laboratory and animal studies
A 2019 study analyzed purified Omomyc in models of non-small cell lung cancer. Cell uptake, disruption of MYC-dependent transcription, and anti-tumor activity were reported in experimental systems, including animal studies. This was an important step in development, as the test was performed on the protein itself rather than relying solely on the expression of a modified gene within the cells.[1]
A later study published in 2025 analyzed MYC inhibition and responses to DNA damage in triple-negative breast cancer. Omomyc collaborated with PARP inhibitors in cell and animal models, including models of resistance. The results support the hypothesis of a combination therapy, but do not constitute a randomized human study confirming improvements in breast cancer treatment outcomes.[3]
Cells derived from patients or tumor models can increase the biological significance of experiments without becoming evidence of patient treatment. The tumor sample grown in the model is still being studied outside the original clinical context. Similarly, analysis of biopsies from patients can identify relationships or biomarkers without demonstrating that the proposed treatment improves survival.
The first study in humans provides particularly important information about feasibility, because it goes beyond cell culture and animal exposure. However, the early dose escalation study is not designed to determine whether the substance is superior to standard treatment. Without a randomized comparator, disease stabilization may be difficult to interpret. The rate of tumor growth is variable; prior therapies may influence the course of the disease, and the tumors included are heterogeneous.
The infusion-related Grade 1 reaction is a category of reported adverse event, not evidence of the absence of more serious or delayed risks. Single dose toxicity limiting the dose is relevant for dose-finding studies, but its interpretation requires consideration of exposure and the observational framework. Small trials provide limited precision in estimating rare events. Safety results should be described as early and specific to the population being studied.
The first published clinical study in humans
The Phase I study report published in 2024 included 22 subjects with advanced solid tumors, evaluated at six dose levels. The primary endpoints were safety and tolerability. The most common adverse events were Grade 1 infusion-related reactions reported in ten participants. There was also one case of dose-limiting toxicity. These results characterize an early study and do not establish an unrestricted safety profile.[2]
Of the 19 participants who were able to assess their response, 12 achieved a previously established activity score after nine weeks, and eight were found to have disease stabilization. One patient classified as having disease stabilization according to RECIST was observed to have a 49% reduction in total tumor volume. The volume observation should not be presented as a 49% rate of objective response or as evidence of partial response according to RECIST. Analysis of the biopsy supported the hypothesis of a molecular target effect. [2]
Clinical trial registries are useful for understanding the direction of a research program. They can indicate the population, intervention, planned endpoints, enrollment status, and sometimes published results. However, they do not replace peer-reviewed analyses for assessing the magnitude of the effect and the quality of the evidence. An active, recruiting, or completed study may still not have publicly available efficacy results.
The status data of October 26, 2026, adopted in this article therefore represents a snapshot of the situation at that time, and not a guarantee of the current status of the registry. Any subsequent changes regarding recruitment or the termination of the studies should be dated separately. Most importantly, hypotheses regarding pancreatic or osteosarcoma should not be presented as effective uses unless the corresponding outcome data support such a conclusion.
Later records of clinical trials
As of the status reviewed on October 26, 2026, the registries indicated further studies regarding pancreatic ductal adenocarcinoma and advanced pancreatic neuroendocrine tumors of high malignancy grade. NCT06059001 was listed as active without recruitment, while NCT06650514 and NCT07089940 were listed as ongoing recruitment. These statuses describe the research activity, not the confirmed efficacy. The records were kept in the research documentation because the status may change. [4] [5] [6]
A later study of biological activity in pancreatic cancer focuses on changes in tumor biopsies and related safety and biomarker issues. Its goal highlights the difference between understanding the behavior of an experimental substance in human tissue and confirming the benefits for the patient. The study goals should not be presented as completed results. [6]
Interaction with the molecular target – a necessary but insufficient step
The MYC-related transcriptional regulation affects numerous cellular processes. A change in the pattern of gene expression located downstream of the pathway may be consistent with the intended mechanism, but interpretation depends on the specificity of the test, the comparator group, the time of sample collection, and the ability to assign the signaling to an intervention. Molecular change may occur without a clinically significant change in tumor burden. In turn, the measured tumor change may have many explanations if appropriate controls are lacking.
Biopsych-based studies add an important level of evidence because they analyze human tissue, not just models. However, a biopsy takes a limited amount of tissue at a specific time. Tumors can contain different cell populations, and the molecular signal in one region does not necessarily represent the entire disease. Biomarker results should be reported along with the sampling method and whether they were exploratory or previously defined.
Studies of associations and attribution of effects
The combination of MYC inhibition with a strategy that affects the response to DNA damage is a hypothesis that is biologically feasible to test. A 2025 experimental study cited provides justification for further analyzing this interaction, also in resistance models. However, the combined experiments raise questions about attributing effects: does the effect outweigh each component separately, or does it depend on the order of exposure, and does a similar relationship exist in humans?.
The clinical comparison also raises safety questions that are not addressed by the preclinical activity of the individual components. The promising interaction in the mouse model does not confirm a ready-made treatment regimen for patients or a universal response in tumors that show MYC activity.
Action mechanisms studied regarding Omomyc
The main strategy is to disrupt the transcription controlled by MYC. MYC usually participates in molecular interactions that regulate gene expression. Omomyc was designed to disrupt this activity. An important consequence is a change in the cellular program controlled by MYC, rather than a simple chemical destruction of each tumor cell upon contact.[1]
A useful mechanistic chain includes delivery, access to the cell interior, interaction with the target, further biological effect, and a clinically relevant outcome. Each step requires evidence. The results of biopsies in Phase I studies support part of this chain, but by themselves they do not confirm longer survival or an advantage over other treatments.[2]
Research on breast cancer from 2025 expands the mechanism to include pathways for responses to DNA damage and the possibility of overcoming PARP inhibition resistance. This suggests why it is worth investigating combinations. However, it does not specify the best partner drug, regimen, tumor subtype, or safety profile for patients beyond the study. [3]
Selectivity also requires careful language. Focusing on a transcription factor relevant to tumors does not mean that normal tissues do not contain this target or cannot be targeted. The therapeutic window must be demonstrated empirically in exposure and safety studies. Targeted molecular selectivity and observed clinical tolerance correspond to related but distinct questions.
Why are the response categories and the nominative pronouns important?
In oncology studies, response categories are defined according to specific measurement principles. Disease stabilization is not equivalent to a partial response, and the individual reduction in tumor volume need not correspond to the RECIST-based classification of response. The reported 49% reduction in tumor volume by one participant in a clinical study is an interesting observation, but it cannot be converted into a percentage of response or a claim for all participants.
The sequence of numbers is equally important. 22 people were included in the study; 19 qualified for the assessment of responses; 12 achieved the indicated assessment after nine weeks, and eight were found to have stabilized the disease. Each denominator answers a different question. Providing only the last number without context could distort the scale and uncertainty of the evidence. The loss of participants from the analysis and the differences in the timing of the assessments should be visible during the interpretation of early oncological studies.
What would allow determining the clinical value?
The next stage of the evidence depends on the target tumor population. More informative studies should define a clinically relevant primary endpoint, an appropriate comparator, eligibility criteria, follow-up time, and methods for handling missing data. Adverse events and benefits should be reported, including discontinuation of treatment and the durability of disease control. If biomarkers are proposed for patient eligibility, their predictive value should be evaluated prospectively rather than inferred from small exploratory subgroups.
An important research question is whether the biological dependence on MYC predicts a response to this specific protein. MYC is important in many malignant tumors, but its presence alone does not constitute a validated qualifying test. Distinguishing between a mechanistic biomarker and a predictive clinical biomarker helps prevent overgeneralization.
Limitations of scientific evidence regarding Omomyc
The first study in humans was small, uncontrolled, and designed primarily to assess safety and to find appropriate doses. The participants had various advanced solid tumors, which makes it particularly difficult to draw broad conclusions about a single type of cancer. Disease stabilization is an important observation, but its significance depends on the biology of the disease, prior progression, duration, and an appropriate comparator.
Modifiers also matter. The results obtained from participants who were later evaluated should not be presented as if they describe everyone who was included. Reporting a complete sequence—those included, those that were assessable, those that reached the assessment point and those that showed a specific outcome—helps avoid the inflated impression of benefit.
Biomarkers introduce additional uncertainty. A potential predictor identified in a small study may not replicate in another population. An exposure or effect marker with a target does not necessarily predict tumor response, and none of them automatically predicts improved survival. Before turning biomarker claims into treatment eligibility criteria, prospective validation is necessary.
Later registration entries show that development is continuing, but the active or recruiting status does not constitute a positive outcome. This review does not treat registered targets, conference abstracts, or the manufacturer's expectations as substitutes for a complete clinical results report.
The main unanswered questions concern who benefits, how long the benefits last, how the results compare with standard treatment, and what risks arise in larger populations or when combined. These are clinical research questions that the strength of the mechanistic rationale alone cannot answer.
Review of scientific evidence
| Source of evidence | Research background | Which confirms | What does it not confirm |
|---|---|---|---|
| Experiments with purified protein (2019) | Cellular and animal models of non-small cell lung cancer | Cell capture and experimental inhibition of MYC | There is no response rate among people nor any benefit in survival |
| Phase I study OMO-103 (2024) | 22 people with advanced solid tumors | Early tolerance, feasibility, and observations of the effect with the goal | Comparative effectiveness and broad long-term safety |
| Experimental studies of combination (2025) | Models of triple negative breast cancer | The hypothesis of interaction with PARP inhibition | An effective or safe combination regimen in humans |
| Later clinical records | Planned or ongoing research concerning specific cancers | Targets, populations and registered study statuses | Positive efficacy results without published data |
This comparison prevents the frequent interpretational error: the evidence that intervention reaches its biological target is not equivalent to evidence that it changes the length of life of patients or their well-being. The evidence base includes valuable mechanistic observations and early clinical results, but the most important patient-level outcomes remain uncharacterized.
Frequently asked questions about Omomyc
1. Does Omomyc mean one of the defined substances?
It refers to a specific concept of modified miniprotein, but publications may include various experimental implementations. The clinical product OMO-103 should be distinguished from transgenic expression systems and modified laboratory constructs. Therefore, precise material identification is necessary before transferring results between studies. [1] [2] The claim regarding identity should also specify whether the material under study was an expression construct, purified research protein, or a clinical formulation. These forms may differ in delivery method and analytical characteristics.
2. What do the available studies on Omomyc confirm?
They confirm the strong experimental rationale for inhibiting MYC and the early feasibility of human studies, including evidence of molecular target interaction. However, they do not translate every mechanistic observation or disease stabilization into proven clinical benefit. Comparative studies regarding specific tumors are still needed to determine the efficacy of treatment.[2] It is crucial to distinguish the evidence of molecular activity from the evidence of patient benefit. Both types are important, but they require additional research designs and measurement of outcomes.
3. Is Omomyc a peptide or a protein?
The most precise term for a clinical molecule composed of 91 residues is a miniprotein. The broad peptide terminology may overlap with the classification of small proteins, but it should not overlook the modified structure or developmental context. Classification clarifies the molecular identity, but does not determine whether the treatment works. [2] Calling the 91-residue modified miniprotein a modified domain better explains the molecular context than the general name of a short peptide. Neither of these terms in itself confirms biological activity or product quality.
4. Is Omomyc the same as MYC?
No. MYC is a biological target, whereas Omomyc is a modified inhibitor derived from its functional region. Misplacing these concepts reverses the intended mechanism. The research strategy is intended to disrupt the activity of MYC, not to supplement it. [1] The distinction also affects the interpretation of biomarkers. A change in transcription regulated by MYC is evidence of the target pathway, not confirmation that MYC has been delivered to the cells.
5. Is OMO-103 a gene therapy?
The clinical approach studied involves administering a miniprotein rather than a gene expression construct. Previous genetic experiments helped to establish the concept, but they should not define the clinical method of delivery. Differentiation is important because the distribution, duration of retention, and safety assessment depend on the method of delivering the intervention. The expression construct and the protein administered have different exposure histories. The results of one approach may justify the other, but they do not confirm their pharmacological equivalence.
6. Does penetration into the cells prove that the substance reaches every tumor?
No. Penetration into selected cell cultures is only one element of delivery. Human tumors differ in their vasculature, architecture, and exposure, therefore tissue measurements and clinical pharmacology are needed. A positive cell penetration experiment does not confirm the uniform delivery to the entire tumor in every patient. Tumor penetration is non-uniform, and biopsy covers only a limited region. Intra-cellular distribution and interaction require separate measurements, not assumptions based on cell culture.
7. Does stabilization of the disease mean a reduction in the tumor size?
Not necessarily. Disease stabilization is a category of response distinct from the criteria for objective tumor reduction, and its clinical significance depends in part on duration and context. It should be reported according to study definitions, rather than being blindly converted into a statement that „the tumor has responded to treatment.” Clinical response categories use previously established measurement principles. The duration of stabilization and the absence of an appropriate control group can significantly influence the significance of the observation.
8. What does the reported reduction in the tumor volume of 49% mean?
This was a volume-based individual observation of a patient still classified according to RECIST as having disease stabilization. Volume and standard response criteria are different measurements. This number is therefore not a proportion of the overall study response or evidence of meeting the standard partial response threshold. [2] Individual observation can be of scientific interest, but it does not constitute an estimate of the average treatment effect. The appropriate denominator and assessment method must remain related to the number.
9. Does the interaction with the molecular target confirm longer survival?
No. The effect with a target indicates that the intervention influenced the intended biological arrangement. Survival is a separate clinical outcome that depends on many factors, therefore it must be measured in an appropriate study and not derived solely from the molecular response. A biomarker may have mechanistic significance, but it does not predict survival. Demonstrating predictive value requires a defined test, threshold, population, and outcome.
10. Can Omomyc be called a treatment for all cancers associated with MYC?
Evidence does not support such a claim. However, a broad-based biological target does not provide uniform dependence, delivery, sensitivity, or safety in all types of tumors. Any intended clinical application requires evidence in the appropriate population, rather than extrapolation from the general significance of the target. MYC is widely present in the biology of tumors, but tumors differ in their dependence on it, delivery of the substance, and compensatory pathways. A broad mechanism does not replace the studies appropriate for a specific indication.
11. Do the tumor research results in mice predict the response rates in humans?
No. They can confirm biological activity in the model and justify clinical trials, but the rates of response in humans require data from humans. Differences in the biology of tumors, immunity, exposure, and prior treatment make direct transfer of numerical values unreliable, even when the preclinical effect is convincing. Even advanced models derived from patients miss part of the original clinical circumstances. Therefore, model efficacy should be treated as the basis for hypotheses regarding benefits in humans.
12. Do PARP inhibitor studies confirm effective combination therapy?
No. The cited study supports the hypothesis of an association in experimental breast cancer models. The clinical benefit and tolerability of such a combination require prospective studies in patients. Resistance gains in the model cannot be presented as a fixed outcome in humans. [3] To interpret the combined experiments, it is necessary to be able to separate the contribution of each component. The clinical safety of combined exposure remains a separate unresolved question.
13. Does the recruitment study confirm its effectiveness?
No. Recruitment means that researchers are looking for evidence, not that a hypothesis has been confirmed. The registries are useful for identifying interventions, populations, and planned outcomes, but the results should be evaluated separately when they become available. The registry status should always include the date of the check. Planned endpoints are not equivalent to results, even if the study has entered the recruitment phase.
14. Can a small Phase I study confirm long-term safety?
No. Early studies characterize tolerance in a limited period of exposure in selected patients. They cannot reliably detect every rare or delayed effect, and combination therapy can introduce additional risks. Before making broad safety claims, larger and longer studies are needed. Rare adverse events and delayed effects may not appear in an early study involving 22 people. Safety conclusions should specify the population being evaluated, the time and exposure.
15. Are the biomarkers already ready to identify all the people who are likely to respond?
This has not been established based on the evidence analyzed in this article. Exploratory biomarkers can be promising without having validated predictive accuracy. Before using them for routine qualification, prospective testing should be performed and distinguished from markers indicating only exposure to a substance or activity of a pathway. Exploratory signals require external or prospective validation. A biomarker associated with target-mediated activity is not automatically a qualified test for treatment qualification.
16. Is the commercial research product equivalent to clinical OMO-103?
The common name does not confirm equivalence. Clinical studies use a characterized experimental product, whereas the unrelated offering does not verify the conformity of the production, formulation, activity, or quality control. Therefore, the published clinical results cannot simply be attributed to material from another supplier. Analytical purity and molecular nomenclature do not confirm the equivalence of the production process, biological activity, or clinical formulation. These properties require direct comparison.
17. What would provide stronger evidence of clinical value?
The most informative studies would be those concerning specific cancers, with appropriate comparators and significant results for patients. They should report the durability of the effect, survival or other relevant benefits, adverse events and validated qualification criteria. Such results would link a promising mechanism with a more precise assessment of the clinical balance of benefits and risks. Studies reporting both positive and negative results, adhering to previously established analyses and using appropriate comparators, would increase the reliability of subsequent clinical conclusions.
Research priorities and other questions
The most important priority is identifying populations in which Omomyc can elicit a repeatable clinical effect. This requires more than just identifying MYC activity. It is necessary to link a specific molecular phenotype to exposure, target-mediated effects, measurable disease control, and clinically relevant outcomes. A predictor identified retrospectively should be evaluated prospectively before it becomes the standard of qualification.
The second priority is the relationship between formulation and exposure. Protein integrity, cellular delivery, tissue distribution, and immune responses can influence whether the results observed in the model can be replicated in patients. Comparing formulations requires a clear description of the material, its biological activity, and the measurement methods used. The trade name or the corresponding number of amino acids are not sufficient.
Hypotheses regarding associations deserve separate, carefully controlled studies. Preclinical interaction with PARP inhibitors provides scientific justification for testing strategies, not proof of improved survival or acceptable toxicity. In appropriate projects, the relative contribution of each component and the effect of previous treatment should be considered.
Transparent reporting is also important. Publications and registries should distinguish between included and assessable participants, primary and exploratory results, and completed observations and planned analyses. Negative and ambiguous results are informative, as they allow for a more precise delineation of the boundaries of the proposed mechanism. This is particularly important for interventions targeting transcription regulators with broad biological significance.
Educational and medical warnings regarding safety and regulations
The article is of a scientific and educational nature. It summarizes the molecular identity, laboratory results, and early clinical evidence described in the cited sources. It does not constitute medical advice or instructions for the selection of treatment, dosage, preparation, or administration of the substance. Omomyc and OMO-103 should be discussed in the context of specific experimental studies and not be considered as alternatives to products offered under similar names.
Experimental anti-cancer activity does not confirm clinical efficacy or safety in a specific individual. Laboratory quality, product formulation, marketing approval status, and clinical evidence are separate issues. Individuals seeking information about the diagnosis or treatment of cancer should consult with a qualified oncology team and use appropriate official product and study information. Regulatory and research status may change, so it is necessary to check them in current primary sources.
Conclusions
Omomyc is a modified MYC-inhibiting miniprotein, and OMO-103 is a product clinically developed based on it. Preclinical studies and early evidence involving humans justify continuing research efforts. However, results should be described precisely. The molecular target effect, tolerability, and disease stabilization provide important information, but they are not equivalent to proven survival benefit or widely effective cancer treatment.
References
- Beaulieu, M. E., Jauset, T., Massó-Vallés, D., Martínez-Martín, S., Rahl, P., Maltais, L., Zacarias-Fluck, M. F., Casacuberta-Serra, S., Serrano Del Pozo, E., Fiore, C., Foradada, L., Cano, V. C., Sánchez-Hervás, M., Guenther, M., Romero Sanz, E., Oteo, M., Tremblay, C., Martín, G., Letourneau, D., … Soucek, L. (2019). Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Science Translational Medicine, 11(484), Article eaar5012. https://doi.org/10.1126/scitranslmed.aar5012
- Garralda, E., Beaulieu, M. E., Moreno, V., Casacuberta-Serra, S., Martínez-Martín, S., Foradada, L., Alonso, G., Massó-Vallés, D., López-Estévez, S., Jauset, T., Corral de la Fuente, E., Doger, B., Hernández, T., Perez-Lopez, R., Arqués, O., Castillo Cano, V., Morales, J., Whitfield, J. R., Niewel, M., … Calvo, E. (2024). Targeting of MYC by OMO-103 in solid tumors: a phase 1 trial. Nature Medicine, 30(3), 762–771. https://doi.org/10.1038/s41591-024-02805-1
- Giuntini, F., González-Larreategui, Í., Herencia-Ropero, A., Casacuberta-Serra, S., Zacarías-Fluck, M. F., Arnal, M., Pedretti, F., Martínez-Martín, S., Thabussot, H., Cano, V. C., Grueso, J., Foradada, L., Serrano, E., López-Estévez, S., Rodriguez, O., Guzman, M., Rodriguez-Hernandez, A., Brasó-Maristany, F., Llop-Guevara, A., … Soucek, L. (2025). Inhibición de MYC por Omomyc causa daño en el ADN y supera la resistencia a PARPi en el cáncer de mama. Cell Reports, 44(12), 116604. https://doi.org/10.1016/j.celrep.2025.116604
- Peptomyc S.L. (n.d.). Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered IV in Patients with PDAC (NCT06059001) [Clinical trial registry record]. ClinicalTrials.gov. Retrieved October 26, 2026, from https://clinicaltrials.gov/study/NCT06059001
- Vall d’Hebron Institute of Oncology. (n.d.). A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma (NCT06650514) [Clinical trial registry record]. ClinicalTrials.gov. Retrieved October 26, 2026, from https://clinicaltrials.gov/study/NCT06650514
- OHSU Knight Cancer Institute. (n.d.). OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (NCT07089940) [Clinical trial registry record]. ClinicalTrials.gov. Retrieved October 26, 2026, from https://clinicaltrials.gov/study/NCT07089940